Ecopipam

Ecopipam (SCH-39166) is a synthetic benzazepine derivative drug that acts as a selective dopamine D1/D5 receptor antagonist, with little affinity for either dopamine D2-like or 5-HT2 receptors. It has sedative, antipsychotic and anorectic effects, and was researched for human use although never approved for medical prescription, mainly because of side effects such as depression and anxiety.

Chemical synthesis
Ecopipam can be synthesized from a simple tetralin derivative:
 * Ecopipam scheme.png

Clinical trials
Ecopipam is currently being used in a clinical trial conducted by the biotechnology company Psyadon for the treatment of Lesch-Nyhan Syndrome, as well as for Tourette syndrome.